Global: Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific TherapiesPharmaceutical ResearchUpdated on Aug 10, 2016 View more like this | Visit LONG BEACH, CA | Contact market reports center |
Hematological malignancies are a class of cancer that affect the blood; lymph nodes and bone marrow; and include numerous forms of leukemia; lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011; with data indicating that lymphomas are more prevalent than leukemia or myeloma. Excluding acute lymphocytic leukemia and Hodgkins lymphoma; these types of malignancy are generally associated with increasing age. Therefore; considering the aging population globally; this class of malignancy is likely to become more prevalent.
Request sample now at : https://marketreportscenter.com/request-sample/319906
The report assesses first-in-class innovation in the hematological cancer pipeline; highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry; with 463 first-in-class products; representing 45.3% of the pipeline with a disclosed molecular target.
Check Discount now at : https://marketreportscenter.com/request-discount/319906
The first-in-class targets in the pipeline are numerous and varied in nature. Cancer immunotherapies are the most common; with a total of 128 across all stages of development; followed by the signal transduction group of targets. The most commercially successful targeted drugs in the market fall into these two categories; including Rituxan (a cancer immunotherapy) and Gleevec (a signal transducer). The other target families have much fewer first-in-class products; reflecting the strong interest in cancer immunotherapies and targets implicated in signal transduction.
Over the past 15 years; the treatment of hematological malignancies has changed significantly; with the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997; which is used to treat multiple types of hematological malignancies; including Non-Hodgkins lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative; targeted therapies.
Browse full report with TOC @ : https://marketreportscenter.com/reports/319906/frontier-pharma-hematological-cancers-highly-innovative-pipeline-continues-trend-towards-targeted-patient-specific-therapies
Connect for more details:
Sam Collins
Market Reports Center
1-646-883-3044 (US)
[email protected]
Request sample now at : https://marketreportscenter.com/request-sample/319906
The report assesses first-in-class innovation in the hematological cancer pipeline; highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry; with 463 first-in-class products; representing 45.3% of the pipeline with a disclosed molecular target.
Check Discount now at : https://marketreportscenter.com/request-discount/319906
The first-in-class targets in the pipeline are numerous and varied in nature. Cancer immunotherapies are the most common; with a total of 128 across all stages of development; followed by the signal transduction group of targets. The most commercially successful targeted drugs in the market fall into these two categories; including Rituxan (a cancer immunotherapy) and Gleevec (a signal transducer). The other target families have much fewer first-in-class products; reflecting the strong interest in cancer immunotherapies and targets implicated in signal transduction.
Over the past 15 years; the treatment of hematological malignancies has changed significantly; with the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997; which is used to treat multiple types of hematological malignancies; including Non-Hodgkins lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative; targeted therapies.
Browse full report with TOC @ : https://marketreportscenter.com/reports/319906/frontier-pharma-hematological-cancers-highly-innovative-pipeline-continues-trend-towards-targeted-patient-specific-therapies
Connect for more details:
Sam Collins
Market Reports Center
1-646-883-3044 (US)
[email protected]
